Hospice Losses Associated with Higher Utilization and Strengthening Head Office Functions
First written in FY2024-Q1. 4 of 11 entries say "Worsened", first in FY2026-H1. Latest entry: 2026-07-30.
Cuc moved to the "Worse" side of this theme in 2025, 5 years after the typical company in this theme (2020).
0 other companies' latest entry also says "Worsened".
- FY2026RestatedAnnual report
「In addition to initial losses from the active opening of new facilities from the beginning of the fiscal year, lower unit prices at existing facilities and other factors resulted in segment profit of ¥980 million, down 2.2% year on year.」
Initial losses at new facilities and lower unit prices at existing facilities continue to be cited as factors weighing on profit. - FY2026-H1WorsenedAnnual report
「Segment profit was ¥139 million, down 79.8% year on year, and EBITDA was ¥811 million, down 29.2% year on year, owing mainly to initial losses during the start-up phase of new facilities and lower unit prices at some existing facilities.」
Initial losses at new facilities and lower unit prices at existing facilities reduced hospice profit and EBITDA year on year. - FY2025-H1MitigatedAnnual report
「Revenue during the current interim consolidated accounting period was ¥6,705 million, up 42.5% year on year, owing mainly to higher occupancy at facilities opened before the previous consolidated fiscal year. Segment profit was ¥690 million, compared with a segment loss of ¥50 million in the previous interim consolidated accounting period, and EBITDA was ¥1,145 million, up 349.6% year on year.」
Higher occupancy at existing facilities and other factors drove the hospice segment from a ¥50 million loss to a ¥690 million profit. - FY2024RestatedAnnual report
「The segment recorded operating profit of ¥349 million, up 82.8% year on year, and EBITDA of ¥697 million, up 46.8% year on year, owing to the full-year contribution from 株式会社ネイチャー, 株式会社A&N and 株式会社ゆう, which became consolidated subsidiaries in January 2023, and 7 new openings during the current consolidated fiscal year.」
Despite continuing costs from new openings, the segment reported operating profit and EBITDA for the full year. - FY2024-Q3MitigatedAnnual report
「Higher costs associated with increased staffing to strengthen head office functions and 6 new openings during the first 3 quarters of the current consolidated cumulative period, compared with 2 openings in the previous period, resulted in operating profit of ¥142 million, down 44.0% year on year, and EBITDA of ¥399 million, down 10.3% year on year.」
Although costs from strengthening head office functions and new openings continued, the cumulative period moved from an operating loss in the previous quarter to operating profit of ¥142 million. - FY2024-Q2RestatedAnnual report
「For segment operating income and EBITDA, increased staffing to strengthen head office functions and 3 new openings during the first 2 quarters of the current consolidated cumulative period, compared with no openings in the same period of the previous year, among other factors, resulted in an operating loss of ¥63 million, compared with operating profit of ¥196 million in the previous period, and EBITDA of ¥113 million, down 65.3% year on year.」
Additional staffing and new openings continued to produce an operating loss and lower EBITDA in the hospice segment. - FY2024-Q1MaterialisedAnnual report
「Due in part to increased staffing to strengthen head office functions and improve facility utilization, operating loss was ¥130 million, compared with operating profit of ¥84 million in the first quarter of the previous consolidated cumulative period, and EBITDA was negative ¥46 million, compared with ¥150 million in the previous period.」
The effects of additional staffing to strengthen head office functions and improve utilization appeared as an operating loss and negative EBITDA during the quarter.